Maxim Group Initiates Coverage on BioHarvest Sciences (NASDAQ:BHST)

Research analysts at Maxim Group assumed coverage on shares of BioHarvest Sciences (NASDAQ:BHST) in a research note issued on Wednesday,Benzinga reports. The firm set a “buy” rating and a $12.00 price target on the stock. Maxim Group’s target price points to a potential upside of 93.86% from the company’s previous close.

Separately, HC Wainwright assumed coverage on BioHarvest Sciences in a research report on Friday, December 6th. They set a “buy” rating and a $14.00 target price on the stock.

BioHarvest Sciences Trading Up 0.6 %

NASDAQ:BHST opened at $6.19 on Wednesday. The stock has a market cap of $101.67 million and a PE ratio of -4.95. BioHarvest Sciences has a 52-week low of $6.09 and a 52-week high of $7.70.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.